Show simple item record

dc.creatorJančić, Ivan
dc.creatorSefik-Bukilica, Mirjana
dc.creatorŽivojinović, Slađana
dc.creatorDamjanov, Nemanja
dc.creatorSpasovski, Vesna
dc.creatorKotur, Nikola
dc.creatorKlaassen, Kristel
dc.creatorPavlović, Sonja
dc.creatorBufan, Biljana
dc.creatorArsenović-Ranin, Nevena
dc.date.accessioned2019-09-02T11:45:02Z
dc.date.available2019-09-02T11:45:02Z
dc.date.issued2015
dc.identifier.issn1452-8258
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/2331
dc.description.abstractBackground: The study was undertaken to assess the influence of functional -308G/A TNF-alpha (rs 1800629) and -174G/C IL-6 (rs1800795) promoter polymorphisms on the therapeutic response to etanercept, a TNF-alpha. blocker, in patients with rheumatoid arthritis (RA). Methods: Seventy-three patients suffering from active RA were studied, at baseline and 6 and 12 months after therapy. The therapeutic response was estimated according to the European League Against Rheumatism response criteria. Patients were genotyped for -308G/A TNF-alpha and -174G/C IL-6 polymorphisms by the PCR-RFLP method, and the influence of genotype on etanercept response was assessed. Results: No difference in the percentage of responders (patients who had DAS28 improvement > 1.2) between patients with the TNF-alpha -308GG and GA and AA genotype was detected after 6 and 12 months of treatment. After 12 months of treatment the percentage of responders was significantly increased in patients with the IL-6 -174GG genotype compared with those with the GC or CC genotype (p=0.006 by Chi-square test). Evaluation of the patients according to their combined IL-6/INF-alpha genotypes showed that patients with the IL-6 -174GG / TNF-alpha -308GG genotype were more frequent among the responders compared to those with other combined genotypes (p=0.022 by Chi-square test). More precisely, all patients with the combined IL-6 -174GG / TNF-alpha -308GG genotype were responders after 12 months of etanercept treatment. Conclusions: The study suggests that patients who are genetically low TNF-alpha and IL-6 producers are the best responders to etanercept therapy.en
dc.publisherDruštvo medicinskih biohemičara Srbije, Beograd i Versita
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175050/RS//
dc.rightsopenAccess
dc.sourceJournal of Medical Biochemistry
dc.titleInfluence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritisen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractСпасовски, Весна; Дамјанов, Немања; Буфан, Биљана; Јанчић, Иван; Сефик-Букилица, Мирјана; Клаассен, Кристел; Павловић, Соња; Котур, Никола; Живојиновић, Слађана; Aрсеновић-Ранин, Невена;
dc.citation.volume34
dc.citation.issue4
dc.citation.spage414
dc.citation.epage421
dc.citation.other34(4): 414-421
dc.citation.rankM23
dc.identifier.wos000363003400004
dc.identifier.doi10.2478/jomb-2014-0060
dc.identifier.pmid28356850
dc.identifier.scopus2-s2.0-84942865195
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs//bitstream/id/1042/2329.pdf
dc.identifier.rcubconv_3410
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record